Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
Sponsors
Bayer
Conditions
Hypertension
Phase 3
Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension
CompletedNCT01788358
Start: 2013-02-14End: 2014-05-01Updated: 2017-10-24
Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil
WithdrawnNCT02047019
Start: 2017-12-01End: 2019-12-08Updated: 2017-05-22